Results 31 to 40 of about 166,471 (381)

End of induction treatment outcomes with a novel cyclophosphamide-based regimen for severe lupus nephritis: Single-center experience from South India

Indian Journal of Rheumatology, 2020
Background: Cyclophosphamide is commonly used along with pulse steroids for induction immunosuppression treatment of severe forms of lupus nephritis (LN).
V Jayaprakash, T Dineshkumar, J Dhanapriya, D Rajasekar, R Sakthirajan, T Balasubramaniyan, Anila A Kurien, N Gopalakrishnan   +7 more
doaj   +1 more source

Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review

Arthritis Research & Therapy, 2023
Background To determine the prevalence of sustained remission/low disease activity (LDA) in patients with rheumatoid arthritis (RA) after discontinuation of tumor necrosis factor inhibitors (TNFi), separately in induction treatment and maintenance ...
Michael M. Ward, Nima Madanchi, Ali Yazdanyar, Nehal R. Shah, Florina Constantinescu   +4 more
doaj   +1 more source

The Role of Mycophenolate Mofetil for the Induction of Remission in ANCA-Associated Vasculitis: A Meta-Analysis

Frontiers in Medicine, 2021
Objectives: The successful introduction of mycophenolate mofetil (MMF) as a treatment for renal allograft reduced the incidence of acute rejection. The inspiring effects obtained by the MMF have led to an evaluation of its therapeutic potency on ANCA ...
Anji Xiong, Chen Xiong, Guancui Yang, Yu Shuai, Deng Liu, Linqian He, Zepeng Guo, Liangwen Zhang, Yi Liu, Yuan Yang, Beibei Cui, Shiquan Shuai   +11 more
doaj   +1 more source

Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial

Arthritis Research & Therapy, 2018
Background The aim was to analyze characteristics that predict remission induction and subsequent loss of remission in patients with moderately active rheumatoid arthritis (RA) who received full-dose combination etanercept plus methotrexate induction ...
Josef S. Smolen, Annette Szumski, Andrew S. Koenig, Thomas V. Jones, Lisa Marshall   +4 more
doaj   +1 more source

Efficacy and safety of vedolizumab in Crohn’s disease in patients from Asian countries in the GEMINI 2 study [PDF]

Intestinal Research, 2021
Background/Aims The efficacy and safety of vedolizumab in moderate-to-severely active Crohn’s disease (CD) were demonstrated in the GEMINI 2 study (NCT00783692). This post-hoc exploratory analysis aimed to assess the efficacy and safety of vedolizumab in
Rupa Banerjee, Sai Wei Chuah, Ida Normiha Hilmi, Deng-Chyang Wu, Suk-Kyun Yang, Dirk Demuth, Dirk Lindner, Shashi Adsul   +7 more
doaj   +1 more source

Rituximab in glomerular diseases: a case series and narrative review

Brazilian Journal of Nephrology, 2021
Introduction: The use of Rituximab (RTX) in glomerular diseases (GD) has increased in the past years, although it is still only used in a small fraction of patients.
Inês Duarte, João Oliveira, Cristina Outerelo, Iolanda Godinho, Marta Pereira, Paulo Fernandes, Sofia Jorge, Joana Gameiro   +7 more
doaj   +2 more sources

Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis

The Saudi Journal of Gastroenterology, 2017
Background/Aims: Treatment of refractory ulcerative colitis (UC) is a clinical challenge, and after biological therapy, monitoring clinical and endoscopic responses is fundamental.
Elham A Hassan, Haidi K Ramadan, Ali A Ismael, Khaled F Mohamed, Madiha M El-Attar, Ihab Alhelali   +5 more
doaj   +1 more source

Maintaining infliximab induced clinical remission with azathioprine and 5-aminosalicylates in acute severe steroid-refractory ulcerative colitis has lower cost and high efficacy (MIRACLE): a multicenter study [PDF]

Intestinal Research, 2022
Background/Aims Infliximab (IFX) has been used to induce and maintain remission in patients with severe steroid-refractory ulcerative colitis (UC). Long-term use of biologics in developing countries is limited by high cost and frequent side effects.
Ramit Mahajan, Arshdeep Singh, Saurabh Kedia, Kirandeep Kaur, Vandana Midha, Pabitra Sahu, Varun Mehta, Dharmatma Singh, Namita Bansal, Khushdeep Dharni, Sandeep Kaushal, Vineet Ahuja, Ajit Sood   +12 more
doaj   +1 more source

Nonlinear analysis of EEG complexity in episode and remission phase of recurrent depression [PDF]

09 December 2019. IJMPR https://onlinelibrary.wiley.com/doi/full/10.1002/mpr.1816, 2018
Biomarkers of Major Depressive Disorder(MDD), its phases and forms have long been sought. Research indicates that the complexity measures of the cortical electrical activity (EEG) might be candidates for this role. To examine whether the complexity of EEG activity, measured by Higuchi fractal dimension (HFD) and sample entropy (SampEn), differs between
arxiv   +1 more source

Bayesian modelling of response to therapy and drug-sensitivity in acute lymphoblastic leukemia [PDF]

arXiv, 2023
Acute lymphoblastic leukemia (ALL) is a heterogeneous hematologic malignancy involving the abnormal proliferation of immature lymphocytes, accounting for most pediatric cancer cases. ALL management in children has seen great improvement in the last decades thanks to better understanding of the disease leading to improved treatment strategies evidenced ...
arxiv